Endovascular Transvenous versus Open Femoropopliteal Bypass
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Study Population—Endovascular Transvenous Group
3.2. Study Population—Control Group
3.3. Clinical Improvements
3.4. Primary Patency
3.5. Primary-Assisted Patency
3.6. Secondary Patency
3.7. Cox Proportional Hazards
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Criqui, M.H.; Matsushita, K.; Aboyans, V.; Hess, C.N.; Hicks, C.W.; Kwan, T.W.; McDermott, M.M.; Misra, S.; Ujueta, F.; on behalf of the American Heart Association Council on Epidemiology and Prevention; et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement from the American Heart Association. Circulation 2021, 144, E171–E191. [Google Scholar] [CrossRef] [PubMed]
- Shamaki, G.R.; Markson, F.; Soji-Ayoade, D.; Agwuegbo, C.C.; Bamgbose, M.O.; Tamunoinemi, B.M. Peripheral Artery Disease: A Comprehensive Updated Review. Curr. Probl. Cardiol. 2022, 47, 101082. [Google Scholar] [CrossRef] [PubMed]
- Bradbury, A.W.; Moakes, C.A.; Popplewell, M.; Meecham, L.; Bate, G.R.; Kelly, L.; Chetter, I.; Diamantopoulos, A.; Ganeshan, A.; Hall, J.; et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): An open-label, randomised, multicentre, phase 3 trial. Lancet 2023, 401, 1798–1809. [Google Scholar] [CrossRef] [PubMed]
- Farber, A.; Menard, M.T.; Conte, M.S.; Kaufman, J.A.; Powell, R.J.; Choudhry, N.K.; Hamza, T.H.; Assmann, S.F.; Creager, M.A.; Cziraky, M.J.; et al. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N. Engl. J. Med. 2022, 387, 2305–2316. [Google Scholar] [CrossRef] [PubMed]
- AbuRahma, A.F. When Are Endovascular and Open Bypass Treatments Preferred for Femoropopliteal Occlusive Disease? Ann. Vasc. Dis. 2018, 11, 25–40. [Google Scholar] [CrossRef] [PubMed]
- Zenunaj, G.; Acciarri, P.; Baldazzi, G.; Cosacco, A.M.; Gasbarro, V.; Traina, L. Endovascular Revascularisation versus Open Surgery with Prosthetic Bypass for Femoro-Popliteal Lesions in Patients with Peripheral Arterial Disease. J. Clin. Med. 2023, 12, 5978. [Google Scholar] [CrossRef]
- Vossen, R.J.; Vahl, A.C.; Fokkema, T.M.; Leijdekkers, V.J.; van Swijndregt, A.M.; Balm, R. Endovascular therapy versus femoropopliteal bypass surgery for medium-length TASC II B and C lesions of the superficial femoral artery: An observational propensity-matched analysis. Vascular 2019, 27, 542–552. [Google Scholar] [CrossRef] [PubMed]
- Rumba, R.; Krievins, D.; Savlovskis, J.; Ezite, N.; Kukulis, I.; Petrosina, E.; Mouttet, L.; Lacis, A.; Zarins, C.K. Long term clinical and functional venous outcomes after endovascular transvenous femoro-popliteal bypass. Int. Angiol. 2022, 41, 509–516. [Google Scholar] [CrossRef] [PubMed]
- Schneider, P.A.; Krievins, D.K.; Halena, G.; Schmidt, A.; Lyden, S.; Lee, V.; Hu, M.; Adelman, M. Venous outcomes at 1 year after using the femoral vein as a conduit for passage of percutaneous femoropopliteal bypass. J. Vasc. Surg. Venous Lymphat. Disord. 2021, 9, 1266–1272.e3. [Google Scholar] [CrossRef]
- Rumba, R.; Krievins, D.; Savlovskis, J.; Ezite, N.; Lacis, A.; Petrosina, E.; Mouttet, L.; Gardovskis, J.; Zarins, C.K. Three-Year Patency Results following Endovascular Transvenous Femoropopliteal Bypass. Medicina 2023, 59, 462. [Google Scholar] [CrossRef]
- Krievins, D.K.; Halena, G.; Scheinert, D.; Savlovskis, J.; Szopiński, P.; Krämer, A.; Ouriel, K.; Nair, K.; Holden, A.; Schmidt, A. One-year results from the DETOUR I trial of the PQ Bypass DETOUR System for percutaneous femoropopliteal bypass. J. Vasc. Surg. 2020, 72, 1648–1658.e2. [Google Scholar] [CrossRef] [PubMed]
- Lyons, O.T.; Behrendt, C.A.; Björck, M. Beyond Wires and Knives: What Can We Learn from BEST-CLI and BASIL-2? Eur. J. Vasc. Endovasc. Surg. 2023, 66, 1–3. [Google Scholar] [CrossRef] [PubMed]
- Bradbury, A.W.; Adam, D.J.; Bell, J.; Forbes, J.F.; Fowkes, F.G.R.; Gillespie, I.; Ruckley, C.V.; Raab, G.M. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. J. Vasc. Surg. 2010, 51 (Suppl. 5), 18S–31S. [Google Scholar] [CrossRef] [PubMed]
- Shu, H.; Xiong, X.; Chen, X.; Sun, X.; Zhang, R.; Wang, R.; Huang, Q.; Zhu, J. Endovascular revascularization vs. open surgical revascularization for patients with lower extremity artery disease: A systematic review and meta-analysis. Front. Cardiovasc. Med. 2023, 10, 1223841. [Google Scholar] [CrossRef] [PubMed]
- Sharrock, M.; Antoniou, S.A.; Antoniou, G.A. Vein Versus Prosthetic Graft for Femoropopliteal Bypass above the Knee: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Angiology 2019, 70, 649–661. [Google Scholar] [CrossRef] [PubMed]
- Ambler, G.K.; Twine, C.P. Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst. Rev. 2018, 2018, CD001487. [Google Scholar] [CrossRef] [PubMed]
- Nierlich, P.; Enzmann, F.K.; Metzger, P.; Dabernig, W.; Akhavan, F.; Martin, J.E.S.; Hitzl, W.; Hölzenbein, T. Arm Vein versus Small Saphenous Vein for Lower Extremity Bypass in the Absence of Both Great Saphenous Veins. Ann. Vasc. Surg. 2021, 70, 341–348. [Google Scholar] [CrossRef] [PubMed]
- Bosiers, M.J.; De Donato, G.; Torsello, G.; Silveira, P.G.; Scheinert, D.; Veroux, P.; Hendriks, J.; Maene, L.; Keirse, K.; Navarro, T.; et al. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results. Cardiovasc. Interv. Radiol. 2023, 46, 1348–1358. [Google Scholar] [CrossRef]
- Ohki, T.; Kichikawa, K.; Yokoi, H.; Iida, O.; Yamaoka, T.; Maeda, K.; Kanaoka, Y. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. J. Vasc. Surg. 2021, 74, 1958–1967.e2. [Google Scholar] [CrossRef]
- Kluckner, M.; Gruber, L.; Wippel, D.; Lobenwein, D.; Westreicher, W.; Pilz, M.; Enzmann, F.K. Long-Term Outcome of Bypass Surgery versus Endovascular Revascularization in Long Femoropopliteal Lesions. J. Clin. Med. 2023, 12, 3507. [Google Scholar] [CrossRef]
- Sarradon, P.; Ozdemir, B.A.; Becquemin, J.P. Technique and early results of percutaneous femoropopliteal bypass with stent graft. J. Vasc. Surg. Cases Innov. Tech. 2023, 9, 101317. [Google Scholar] [CrossRef] [PubMed]
Endovascular Transvenous Group | Control Group | ||
---|---|---|---|
Age | 64.9 years (SD = 8.3) | 70.6 (SD = 6.6) | p ≤ 0.001 |
Male | 92.3% | 70.4% | p ≤ 0.01 |
Rutherford category | 3—84.6% 4—9.6% 5—5.8% | 2—0.7% 3—41.9% 4—46.0% 5—11.3% | p ≤ 0.001 |
Comorbidities | Hypertension—88.4% Smoking—83.3% Coronary artery disease—28.8% Diabetes mellitus—25.9% | Hypertension—84.7% Smoking—87.8% Coronary artery disease—31.3% Diabetes mellitus—28.2% | p ≥ 0.5 |
ABI at baseline | 0.62 (SD = 0.16) | 0.56 (SD = 0.11) | p ≤ 0.001 |
SFA lesions length (cm, mean) | 27.8 cm (SD = 4.8) | 28.5 cm (SD = 5.2) | p ≥ 0.5 |
Run-off vessels | 1—4/54 (7%) 2—19/54 (35%) 3—31/54 (58%) | 0—2/124 (0.9%) 1—12/124 (5.5%) 2—51/124 (23.2%) 3—59/124 (26.8%) | p ≥ 0.5 |
Patency | Transvenous Endovascular | Venous Bypass | Prosthetic Bypass | p Value |
---|---|---|---|---|
Primary | ||||
| 79.6% | 90.9% | 72.5% | 0.015 vein vs. prosthetic |
| 58.5% | 84.1% | 42.5% | <0.001 vein vs. prosthetic 0.006 vein vs. endo |
| 46.2% | 70.5% | 22.5% | <0.05 |
Primary-assisted | ||||
| 88.9% | 93.2% | 75.9% | 0.013 vein vs. prosthetic |
| 79.2% | 86.4% | 48.1% | <0.001 vein vs. prosthetic 0.002 endo vs. prosthetic |
| 69.2% | 77.3% | 26.6% | <0.001 |
Secondary | ||||
| 92.6% | 85.2% | 75.6% | 0.012 vein vs. prosthetic 0.021 endo vs. prosthetic |
| 86.8% | 86.4% | 48.7% | <0.001 |
| 76.9% | 77.3% | 28.2% | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rumba, R.; Krievins, D.; Ezite, N.; Lacis, A.; Mouttet, L.; Vavere, A.L.; Zarins, C.K. Endovascular Transvenous versus Open Femoropopliteal Bypass. Medicina 2024, 60, 777. https://doi.org/10.3390/medicina60050777
Rumba R, Krievins D, Ezite N, Lacis A, Mouttet L, Vavere AL, Zarins CK. Endovascular Transvenous versus Open Femoropopliteal Bypass. Medicina. 2024; 60(5):777. https://doi.org/10.3390/medicina60050777
Chicago/Turabian StyleRumba, Roberts, Dainis Krievins, Natalija Ezite, Aigars Lacis, Ludovic Mouttet, Anda L. Vavere, and Christopher K. Zarins. 2024. "Endovascular Transvenous versus Open Femoropopliteal Bypass" Medicina 60, no. 5: 777. https://doi.org/10.3390/medicina60050777